In one of the few pieces of significant legislation to win bipartisan support in 2012, Congress reauthorizes the Food and Drug Administration's user-fee acts for the drug and medical device industries and establishes first-time user-fee programs for the biosimilars and generic drug sectors.
FULL STORY »